Long‐term effectiveness and tolerability of apremilast in patients with moderate‐to‐severe plaque psoriasis: A 5‐year multicentre retrospective study—<scp>IL PSO</scp> (Italian landscape psoriasis)-Reference-Cited by-同舟云学术

Long‐term effectiveness and tolerability of apremilast in patients with moderate‐to‐severe plaque psoriasis: A 5‐year multicentre retrospective study—IL PSO (Italian landscape psoriasis)

Published:2024-03-29 Issue: Volume: Page:
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:Acad Dermatol Venereol

Author:

Gargiulo L.¹²^ORCID,Ibba L.¹²^ORCID,Malagoli P.³,Amoruso F.⁴,Balato A.⁵^ORCID,Bardazzi F.⁶,Burlando M.⁷,Carrera C. G.⁸,Dapavo P.⁹,Dini V.¹⁰^ORCID,Gaiani F. M.³^ORCID,Girolomoni G.¹¹^ORCID,Guarneri C.¹²,Lasagni C.¹³,Loconsole F.¹⁴,Marzano A. V.⁸¹⁵^ORCID,Maurelli M.¹¹^ORCID,Megna M.¹⁶^ORCID,Travaglini M.¹⁷,Costanzo A.¹²^ORCID,Narcisi A.¹

Affiliation:

1. Dermatology Unit IRCCS Humanitas Research Hospital Milan Italy

2. Department of Biomedical Sciences Humanitas University Milan Italy

3. Department of Dermatology Dermatology Unit Azienda Ospedaliera San Donato Milanese Milan Italy

4. Dermatology Unit Azienda Ospedaliera di Cosenza Cosenza Italy

5. Dermatology Unit University of Campania L. Vanvitelli Naples Italy

6. Dermatology Unit IRCCS Azienda Ospedaliero‐Universitaria di Bologna, Policlinico S. Orsola Malpighi Bologna Italy

7. Department of Dermatology, Dipartimento di Scienze Della Salute (DISSAL) University of Genoa, IRCCS Ospedale Policlinico San Martino Genoa Italy

8. Dermatology Unit Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan Italy

9. Department of Biomedical Science and Human Oncology, Second Dermatologic Clinic University of Turin Turin Italy

10. Dermatology Unit Department of Clinical and Experimental Medicine Ospedale Santa Chiara Pisa Italy

11. Department of Medicine, Section of Dermatology and Venereology University of Verona Verona Italy

12. Department of Biomedical and Dental Sciences and Morphofunctional Imaging, Unit of Dermatology University of Messina, AOU Policlinico G. Martino Messina Italy

13. Dermatological Clinic, Department of Specialized Medicine University of Modena Modena Italy

14. Department of Dermatology University of Bari Bari Italy

15. Department of Pathophysiology and Transplantation Università Degli Studi di Milano Milan Italy

16. Section of Dermatology, Department of Clinical Medicine and Surgery University of Naples Federico II Naples Italy

17. U.O.S.D. Dermatologica – Centro per la Cura Della Psoriasi Brindisi Italy

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdv.20003

Reference8 articles.

1. European Medicines Agency. Otezla (apremilast): summary of product characteristics.2015[cited 2023 December 6]. Available from:https://www.ema.europa.eu/en/medicines/human/EPAR/otezla

2. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 1: treatment and monitoring recommendations

3. Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis

4. A real‐world, non‐interventional, prospective study of the effectiveness and safety of apremilast in bio‐naïve adults with moderate plaque psoriasis treated in the routine care in Greece – the ‘ APRAISAL ’ study